Alkotinib

奥卡替尼

Report date: 2024/05/19 20:00:11
NME

Base Information

Drug NameAlkotinib
Drug Alias NameAlkotinib - Suzhou Zelgen BiopharmaceuticalsZG-0418
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesSuzhou Zelgen Biopharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesSuzhou Zelgen Biopharmaceuticals Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A